{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:33:27Z","timestamp":1793694807878,"version":"4.5.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.wneu.2024.08.166","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T14:51:36Z","timestamp":1725634296000},"page":"e556-e566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Significance and Priority of Surgical Resection as Therapeutic Strategy Based on Clinical Characteristics of Brain Metastases from Renal Cell Carcinoma"],"prefix":"10.1016","volume":"191","author":[{"given":"Yohei","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7500-3850","authenticated-orcid":false,"given":"Kyoichi","family":"Tomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Teshigawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2716-0701","authenticated-orcid":false,"given":"Takuya","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzuru","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Akasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6474-6317","authenticated-orcid":false,"given":"Toshihide","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2024.08.166_bib1","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2024.08.166_bib2","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Reni","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2024.08.166_bib3","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.wneu.2024.08.166_bib4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2024.08.166_bib5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/cncr.25452","article-title":"Sunitinib in metastatic renal cell carcinoma patients with brain metastases","volume":"117","author":"Gore","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.wneu.2024.08.166_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/bjc.2015.196","article-title":"Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma","volume":"113","author":"Gore","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.wneu.2024.08.166_bib7","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.wneu.2024.08.166_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2024.08.166_bib9","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2024.08.166_bib10","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A\u00a0randomized, double-blinded phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update","volume":"49","author":"Sternberg","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.wneu.2024.08.166_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100805","article-title":"Survival benefit with resection of brain metastases from renal cell carcinoma in the setting of molecular targeted therapy and\/or immune therapy","volume":"46","author":"Huntoon","year":"2022","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.wneu.2024.08.166_bib12","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.3171\/2023.5.FOCUS23122","article-title":"Association between systemic treatment with immune checkpoint inhibitor therapy in renal cell carcinoma and reduced risk of brain metastasis development","volume":"55","author":"Damante","year":"2023","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.wneu.2024.08.166_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.564382","article-title":"Immune checkpoint inhibitors and survival outcomes in brain metastases: a time series-based meta-analysis","volume":"10","author":"Hu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.wneu.2024.08.166_bib14","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.3171\/2023.5.FOCUS23122","article-title":"Association between systemic treatment with immune checkpoint inhibitor therapy in renal cell carcinoma and reduced risk of brain metastasis development","volume":"55","author":"Mark","year":"2023","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.wneu.2024.08.166_bib15","article-title":"Survival benefit with resection of brain metastases from renal cell carcinoma in the setting of molecular targeted therapy and\/or immune therapy","volume":"46","author":"Kristin","year":"2022","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.wneu.2024.08.166_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11060-009-9839-y","article-title":"Management of brain metastases: the indispensable role of surgery","volume":"92","author":"Al-Shamy","year":"2009","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.08.166_bib18","first-page":"v4","article-title":"Surgical advances in the management of brain metastases","volume":"3","author":"Ng","year":"2021","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.wneu.2024.08.166_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12883-015-0476-0","article-title":"Intraoperative neuromonitoring for function-guided resection differs for supratentorial motor eloquent gliomas and metastases","volume":"15","author":"Obermueller","year":"2015","journal-title":"BMC Nuerol"},{"key":"10.1016\/j.wneu.2024.08.166_bib20","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.wneu.2014.07.034","article-title":"Minimally invasive endoscopic resection of intraparenchymal brain tumors","volume":"82","author":"Plaha","year":"2014","journal-title":"World Neurosurg"},{"key":"10.1016\/j.wneu.2024.08.166_bib21","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1227\/01.NEU.0000372204.85227.BF","article-title":"Initial clinical experience with a high-definition exoscope system for microneurosurgery","volume":"67","author":"Mamelak","year":"2010","journal-title":"Neurosurgery"},{"key":"10.1016\/j.wneu.2024.08.166_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.wneu.2017.05.109","article-title":"Vitom-3D for exoscope neurosurgery initial experience in cranial and spinal procedures","volume":"105","author":"Oertel","year":"2017","journal-title":"World Neurosurg"},{"issue":"1 suppl","key":"10.1016\/j.wneu.2024.08.166_bib23","first-page":"349","article-title":"Image-guided craniotomy for cerebral metastases: techniques and outcome","volume":"61","author":"Tan","year":"2007","journal-title":"Neurosurgery (Baltim)"},{"key":"10.1016\/j.wneu.2024.08.166_bib24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clineuro.2014.01.023","article-title":"The prognostic significance of surgically treated by hydrocephalus in leptomeningeal metastases","volume":"119","author":"Jung","year":"2014","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.wneu.2024.08.166_bib25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11060-010-0512-2","article-title":"Ventriculoperitoneal shunt for hydrocephalus caused by central nervous system metastasis","volume":"104","author":"Lee","year":"2011","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.08.166_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210074","article-title":"Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: a single-center retrospective study","volume":"14","author":"Mitsuya","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.wneu.2024.08.166_bib27","first-page":"1753","article-title":"Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation","volume":"9","author":"Morichika","year":"2016","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.wneu.2024.08.166_bib28","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1212\/01.WNL.0000160396.69050.DC","article-title":"Ventriculoperitoneal shunt in patients with leptomeningeal metastasis","volume":"64","author":"Omuro","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.wneu.2024.08.166_bib29","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s00595-008-3909-1","article-title":"Gefatinib and a ventriculo-peritoneal shunt to manage carcinomatous meningitis from non-small cell lung cancer: report of two cases","volume":"39","author":"So","year":"2009","journal-title":"Surg Today"},{"key":"10.1016\/j.wneu.2024.08.166_bib30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.prp.2006.12.002","article-title":"Prognostic significance of vascular endothelial growth factor in clear cell renal cell carcinoma","volume":"203","author":"Djordjevic","year":"2007","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.wneu.2024.08.166_bib31","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3322\/caac.21729","article-title":"An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma","volume":"72","author":"Hasanov","year":"2022","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.wneu.2024.08.166_bib32","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1136\/jnnp.2007.130534","article-title":"Efficacy of gamma knife surgery for control of peritumoral oedema associated with metastatic brain tumors","volume":"79","author":"Shuto","year":"2008","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.wneu.2024.08.166_bib33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11060-010-0170-4","article-title":"Treatment strategy for metastatic brain tumors from renal cell carcinoma: selection of gamma knife surgery or craniotomy for control of growth and peritumoral edema","volume":"98","author":"Shuto","year":"2010","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.08.166_bib34","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.wneu.2024.08.166_bib35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11060-023-04325-3","article-title":"Anatomical and surgical characteristics correlate with pachymeningeal failure in patients with brain metastases after neurosurgical resection and adjuvant stereotactic radiosurgery","volume":"163","author":"Kalyvas","year":"2023","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.08.166_bib36","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1227\/01.NEU.0000341535.53720.3E","article-title":"Comparative risk of leptomeningeal dissemination of cancer after surgery or stereotactic radiosurgery for a single supratentorial solid tumor metastasis","volume":"64","author":"Suki","year":"2009","journal-title":"Neurosurgery"},{"key":"10.1016\/j.wneu.2024.08.166_bib37","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10147-021-02083-8","article-title":"Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection of brain metastasis: a case series of 20 patients","volume":"27","author":"Deguchi","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.wneu.2024.08.166_bib38","article-title":"Neoadjuvant stereotactic radiosurgery for brain metastases: systematic review and meta-analysis of the literature and ongoing clinical trials","volume":"14","author":"Palmisciano","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.wneu.2024.08.166_bib39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1227\/NEU.0000000000001096","article-title":"Comparing preoperative with postoperative stereotactic radiosurgery for resectable brain metastases: a multi-institutional analysis","volume":"79","author":"Patel","year":"2016","journal-title":"Neurosurgery"},{"key":"10.1016\/j.wneu.2024.08.166_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2018.00959","article-title":"Preoperative stereotactic radiosurgery for brain metastases","volume":"9","author":"Routman","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.wneu.2024.08.166_bib41","doi-asserted-by":"crossref","first-page":"182.e9","DOI":"10.1016\/j.urolonc.2018.10.021","article-title":"Renal cell carcinoma and brain metastasis, questioning the dogma of role for cytoreductive nephrectomy","volume":"37","author":"Daugherty","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.wneu.2024.08.166_bib42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0360-3016(95)02029-2","article-title":"A\u00a0review of human cell radiosensitivity in\u00a0vitro","volume":"34","author":"Deschavanne","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12 Suppl","key":"10.1016\/j.wneu.2024.08.166_bib43","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2519::AID-CNCR26>3.0.CO;2-E","article-title":"Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in\u00a0vitro and in\u00a0vivo in human renal cell carcinoma xenografts","volume":"80","author":"Ning","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.wneu.2024.08.166_bib44","first-page":"188","article-title":"Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases","volume":"132","author":"Juloori","year":"2020","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2024.08.166_bib45","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/sj.bjc.6603327","article-title":"Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable","volume":"95","author":"Vogl","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.wneu.2024.08.166_bib46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1359-6349(06)70062-3","article-title":"Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys","volume":"4","author":"Patyna","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.wneu.2024.08.166_bib47","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/annonc\/mdp411","article-title":"Incidence of brain metastases in renal cell carcinoma treated with sorafenib","volume":"21","author":"Massard","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.wneu.2024.08.166_bib48","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.wneu.2024.08.166_bib49","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875024015353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875024015353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T01:35:45Z","timestamp":1749692145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875024015353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":48,"alternative-id":["S1878875024015353"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2024.08.166","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Significance and Priority of Surgical Resection as Therapeutic Strategy Based on Clinical Characteristics of Brain Metastases from Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2024.08.166","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}